GeoVax Labs, Inc. has entered into an exclusive worldwide license agreement with Emory University for intellectual property covering the use of Gedeptin® in combination with immune checkpoint inhibitors. The licensed technology supports the use of gene-directed enzyme prodrug therapy to enhance the anti-tumor activity of checkpoint blockade, a development that strengthens GeoVax's immuno-oncology strategy and expands its intellectual property foundation for combination therapies across solid tumors.
The exclusive license provides GeoVax with global rights to patent applications and associated know-how covering the combination of Gedeptin with immune checkpoint inhibitors within a defined field of use. This intellectual property estate is intended to support GeoVax's current and planned clinical programs evaluating Gedeptin in combination with ICIs, including its recently announced neoadjuvant strategy in head and neck cancer and its ongoing evaluation of additional solid tumor indications. As checkpoint inhibitors continue to move earlier in treatment paradigms, including first-line and neoadjuvant settings, Gedeptin's localized tumor-debulking and immune-sensitizing mechanism may provide an important opportunity to enhance and extend immune checkpoint inhibitor efficacy.
David A. Dodd, Chairman and Chief Executive Officer of GeoVax, stated that the license further consolidates the company's long-standing relationship with Emory University and meaningfully strengthens its intellectual property position around Gedeptin-based combination therapies. "Checkpoint inhibitors have transformed cancer care, but many patients still fail to achieve durable responses," Dodd added. "The licensed Emory technology reinforces the scientific rationale for combining Gedeptin with ICIs to potentially convert immunologically 'cold' tumors into more responsive targets."
GeoVax has previously reported encouraging clinical and translational data demonstrating that Gedeptin's intratumoral delivery approach can induce localized tumor cell death while promoting immune activation within the tumor microenvironment. This effect may be complementary to systemic checkpoint inhibition. The company has announced plans to evaluate Gedeptin in combination with immune checkpoint inhibitors in a Phase 2 neoadjuvant clinical trial in head and neck squamous cell carcinoma, as well as preclinical assessments in additional solid tumor settings. The Emory license provides a strengthened IP foundation to support these efforts and potential future partnerships.
Gedeptin is a gene-directed enzyme prodrug therapy delivered intratumorally using a non-replicating viral vector encoding purine nucleoside phosphorylase. Following administration of a systemically delivered prodrug, the encoded enzyme converts the prodrug into a cytotoxic agent directly within the tumor microenvironment. This localized approach is designed to selectively destroy tumor cells while promoting immune recognition and minimizing systemic toxicity. Gedeptin has received Orphan Drug Designation for oral and pharyngeal cancers. For more information about GeoVax's broader pipeline and development priorities, visit https://www.geovax.com.
The strategic license acquisition represents a significant step in addressing one of immuno-oncology's persistent challenges: converting non-responsive tumors into immunotherapy-sensitive targets. As combination therapies become increasingly central to cancer treatment paradigms, GeoVax's strengthened intellectual property position could accelerate development of more effective treatment options for patients with solid tumors who currently experience limited benefits from checkpoint inhibitors alone.
